[breadcrumb_custom]

ATAI Life Sciences N.V. (NASDAQ: ATAI)’s Stock Performance and Outlook

In the latest trading session, 0.52 million ATAI Life Sciences N.V. (NASDAQ:ATAI) shares changed hands as the company’s beta touched 0.91. With the company’s most recent per share price at $1.86 changing hands around $0.13 or 7.51% at last look, the market valuation stands at $308.76M. ATAI’s current price is a discount, trading about -28.49% off its 52-week high of $2.39. The share price had its 52-week low at $1.02, which suggests the last value was 45.16% up since then. When we look at ATAI Life Sciences N.V.’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 1.92.

ATAI Life Sciences N.V. (NASDAQ:ATAI) trade information

Instantly ATAI is in green as seen in intraday trades today. With action 6.89%, the performance over the past five days has been green. The jump to weekly highs of 1.8600 added 7.51% to the stock’s daily price. The company’s shares are showing year-to-date upside of 31.91%, with the 5-day performance at 6.89% in the green. However, in the 30-day time frame, ATAI Life Sciences N.V. (NASDAQ:ATAI) is -7.01% down. Looking at the short shares, we see there were 4.75 million shares sold at short interest cover period of 2.5 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

ATAI Life Sciences N.V. (ATAI) estimates and forecasts

Data shows that the ATAI Life Sciences N.V. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 10.71% over the past 6 months, a 69.39% in annual growth rate that is considerably higher than the industry average of 16.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for ATAI Life Sciences N.V. will rise 42.90%, while the growth in revenue is estimated to hit 19.00% for the next quarter. Year-over-year growth is forecast to reach 93.10% up from the last financial year.

Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of $190k. The company’s revenue for the corresponding quarters a year ago was $38k and $40k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 400.00%.

On Key

Related Posts